A Study to Test the Efficacy, Safety, and Tolerability of Bepranemab (UCB0107) in Patients With Mild Cognitive Impairment or Mild Alzheimer's Disease (AD)

Inclusion Criteria: * 50 to 80 years of age * Diagnosis of prodromal/mild cognitive impairment (MCI) due to Alzheimer's Disease (AD) or mild AD according to National Institute of Aging-Alzheimer's Association (NIA-AA) * A global Clinical Dementia Rating (CDR) score of 0.5 to 1.0 and CDR-Memory Box (CDRMB) score ≥0.5 at Screening and Baseline * Score of ≤85 for the delayed recall domain of the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) at Screening * Mini-Mental State Examination (MMSE) score ≥20 at Screening * Participant has an identified informant that has and will maintain sufficient contact (minimum of 5 hours per week) with the participant to be able to provide accurate information on the participant's cognitive, functional, and emotional states and of the participant's personal care * At least 6 years of formal education after the age of 5 or work experience to exclude mental deficits other than prodromal or mild AD dementia * Evidence of cerebral Aβ accumulation by either positive amyloid assessment by either positron emission tomography (PET) scan or cerebrospinal fluid pTau181/Aβ1-42 ratio assessment Exclusion Criteria: * Any evidence of a condition that may affect cognition other than AD * Contraindications to PET imaging * Inability to tolerate or contraindication to magnetic resonance imaging * Any serious medical condition or abnormality that in the opinion of the investigator would preclude safe participation in and completion …